End-to-end eCTD publishing and regulatory operations support — for emerging biotechs, mid-size sponsors, and established pharmaceutical companies that demand flawless execution.
A single formatting error, broken hyperlink, or missed validation requirement can delay your program by months. Don't let a technical oversight derail your IND, NDA, or BLA.
Whether you're a startup filing your first IND or an established sponsor managing a complex lifecycle submission, the technical compliance requirements of eCTD publishing — correct formatting, hyperlinking, bookmarks, PDF specifications, and validation — are a discipline that demands a dedicated specialist.
A Refusal to File from Health Canada or an FDA validation failure doesn't just delay your timeline. It delays your program, erodes investor confidence, and can set your organization back by six to twelve months.
Having worked inside top-tier sponsors (Roche, AstraZeneca, Amgen) and a major global CRO (ICON plc), Nisha understands both what health authorities expect and what execution teams routinely miss.
Regulatory deadlines don't move. Nisha integrates quickly into your team, works independently, and delivers compliant submissions under the tightest timelines — from IND to BLA.
From submission planning and readiness assessment through final validation and agency filing — Nisha handles the full regulatory operations workflow across all submission types and jurisdictions.
In regulatory submissions, the difference between approval and rejection is often a single broken hyperlink. Nisha's meticulous, detail-first approach ensures nothing slips through.
From first-in-human INDs to complex BLA submissions — across emerging biotechs, mid-size sponsors, and established pharmaceutical companies.
Full compilation, formatting, hyperlinking, bookmarking, and validation of eCTD submission packages for FDA, Health Canada, and EMA — across all submission types and lifecycle stages.
Specialized support for Canadian regulatory submissions including New Drug Submissions and Abbreviated New Drug Submissions, formatted and validated to Health Canada's exact specifications.
Flexible publishing capacity and regulatory operations support for internal teams facing deadline pressure, headcount gaps, or complex submission requirements — at any stage of your pipeline.
A rigorous, predictable four-step process designed to eliminate the chaos that causes most submission failures.
A focused 30-minute call to understand your submission type, timeline, current document status, and regulatory authority requirements. No obligation — just clarity.
A structured review of your existing documentation to identify gaps, formatting issues, and validation risks before publishing begins. Prevents costly rework downstream.
End-to-end eCTD compilation using Veeva Vault RIM, Lorenz DocuBridge, and ISI Toolbox. Full hyperlink verification, bookmark validation, and PDF specification compliance.
Submission to the regulatory authority via FDA ESG or Health Canada's electronic gateway, with full tracking through to agency acknowledgment.
Nisha Minhas brings over 13 years of pharmaceutical experience across some of the world's most demanding regulatory environments — from global Big Pharma to major CROs. She has supported submissions ranging from first-in-human INDs to complex lifecycle BLAs across multiple jurisdictions.
That breadth of experience — across sponsor and service provider environments, across company sizes, and across regulatory authorities — is what sets her apart from both large CROs and generalist regulatory advisors.
Work With NishaPublishing is not something you do after the documents are ready. eCTD compilation, hyperlinking, validation, and QC require significant lead time. Organizations that treat it as a last-minute task face validation failures and delayed filings — regardless of company size.
Scientifically complete documents can still fail technically. Correct formatting, PDF specifications, bookmarks, and hyperlinks are equally critical. A single broken cross-reference can result in a Refusal to File.
Bringing Reg Ops in at the publishing stage — rather than during document planning — is one of the most common and costly mistakes across the industry. Early involvement prevents rework and protects your timeline.
Whether you have an IND deadline in six weeks, a complex BLA in progress, or you need overflow publishing capacity for your internal team — book a 30-minute strategy call to discuss your requirements.
30 minutes · No obligation · Focused on your specific submission needs
Book Your Call